Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
504-04-004 ISMRM Abstract

Evaluation of Chemotherapy Response Using Hyperpolarized ¹³C MRI in PDX Models of Metastatic Prostate Cancer

Primary: Body - Prostate
Secondary: Preclinical Animal & in vitro MR - Biomarkers
504-04-004 · Cancer Imaging and Spectroscopy · Wednesday, 13 May, 4:00 PM–5:50 PM · Ballroom East
Keywords: Prostate cancer Hyperpolarized 13C MRI Chemotherapy Animal mouse model Metabolic biomarker
Accepted
Meetu Wadhwa1, Said Al Muzahimi1, Ivina Mali1, Rosalie Nolley1, Andrea Capozzi2, Sule Sahin1, Jennifer Lewis1, Peder Larson1, John Kurhanewicz1, Donna Peehl1, Renuka Sriram 1
1Department of Radiology and Biomedical Imaging, University Of California, San Francisco (UCSF), United States of America
2LIFMET, Institute of Physics, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
Presenting Author: Renuka Sriram

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(11):2846-2850. doi:10.1158/1078-0432.CCR-13-3309 [doi]
2. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89. doi:10.14740/wjon1191 [doi]
3. Drake CG. Visceral metastases and prostate cancer treatment: “die hard,” “tough neighborhoods,” or “evil humors”? Oncol Williston Park N. 2014;28(11):974-980. PMID-25403629
4. Lin D, Wyatt AW, Xue H, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014;74(4):1272-1283. doi:10.1158/0008-5472.CAN-13-2921-T [doi]
5. Nguyen HM, Vessella RL, Morrissey C, et al. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. The Prostate. 2017;77(6):654-671. doi:10.1002/pros.23313 [doi]
6. Agarwal S, Upadhyay D, Sun J, et al. Impact of Metastatic Microenvironment on Physiology and Metabolism of Small Cell Neuroendocrine Prostate Cancer Patient-Derived Xenografts. Cancers. 2025;17(14):2385. doi:10.3390/cancers17142385 [doi]
7. Sahin SI, Ji X, Agarwal S, et al. Metabolite-Specific Echo Planar Imaging for Preclinical Studies with Hyperpolarized 13C-Pyruvate MRI. Tomogr Ann Arbor Mich. 2023;9(2):736-749. doi:10.3390/tomography9020059 [doi]
8. Larson PEZ, Chen HY, Gordon JW, et al. Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients. NMR Biomed. 2018;31(11):e3997. doi:10.1002/nbm.3997 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/504-04-004